Venus Medtech (Hangzhou) Inc. (HKG:2500)
Hong Kong · Delayed Price · Currency is HKD 2.100
-0.010 (-0.47%)
Apr 20, 2026, 4:08 PM HKT
Venus Medtech (Hangzhou) Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 306.79 | 470.83 | 491.37 | 406.46 | 415.86 | |
Revenue Growth (YoY) | -34.84% | -4.18% | 20.89% | -2.26% | 50.65% |
Cost of Revenue | 94.95 | 103.09 | 102.17 | 92.46 | 91.52 |
Gross Profit | 211.83 | 367.75 | 389.21 | 314 | 324.34 |
Selling, General & Admin | 292.24 | 391.09 | 454.26 | 436.76 | 344.65 |
Research & Development | 267.4 | 341.19 | 524.92 | 527.45 | 258.34 |
Other Operating Expenses | - | - | - | 21.97 | 3.19 |
Operating Expenses | 557.15 | 733.37 | 977.75 | 986.18 | 606.17 |
Operating Income | -345.32 | -365.62 | -588.55 | -672.19 | -281.83 |
Interest Expense | -17.81 | -16.65 | -62.72 | -44.62 | -1.91 |
Interest & Investment Income | 5.02 | 10.35 | 34.46 | 34.65 | 49.48 |
Earnings From Equity Investments | -2.1 | -4.15 | -12.38 | -13.94 | -11.71 |
Currency Exchange Gain (Loss) | - | 0.88 | 2.26 | 81.73 | 10.01 |
Other Non Operating Income (Expenses) | -59.54 | -222.08 | -65.7 | -104.45 | -145.84 |
EBT Excluding Unusual Items | -419.76 | -597.28 | -692.63 | -718.82 | -381.79 |
Merger & Restructuring Charges | - | - | - | -15.8 | - |
Impairment of Goodwill | - | - | -231.26 | -304.3 | -189.96 |
Gain (Loss) on Sale of Investments | - | -81.41 | 45.48 | -5.69 | 1.33 |
Asset Writedown | - | -62.03 | -17.52 | -111.74 | -46.19 |
Other Unusual Items | 14.87 | - | 160.59 | - | 239.05 |
Pretax Income | -404.89 | -740.71 | -735.34 | -1,156 | -377.56 |
Income Tax Expense | 2.81 | -23.34 | -6.28 | -34.3 | -6.16 |
Earnings From Continuing Operations | -407.69 | -717.37 | -729.06 | -1,122 | -371.39 |
Minority Interest in Earnings | - | 3.07 | 25.3 | 64.34 | -2.24 |
Net Income | -407.69 | -714.31 | -703.75 | -1,058 | -373.64 |
Net Income to Common | -407.69 | -714.31 | -703.75 | -1,058 | -373.64 |
Shares Outstanding (Basic) | 438 | 438 | 438 | 438 | 439 |
Shares Outstanding (Diluted) | 438 | 438 | 438 | 438 | 439 |
Shares Change (YoY) | - | - | - | -0.15% | 7.16% |
EPS (Basic) | -0.93 | -1.63 | -1.61 | -2.42 | -0.85 |
EPS (Diluted) | -0.93 | -1.63 | -1.61 | -2.42 | -0.85 |
Free Cash Flow | - | -10.18 | -870.66 | -899.44 | -538.99 |
Free Cash Flow Per Share | - | -0.02 | -1.99 | -2.05 | -1.23 |
Gross Margin | 69.05% | 78.11% | 79.21% | 77.25% | 77.99% |
Operating Margin | -112.56% | -77.65% | -119.78% | -165.38% | -67.77% |
Profit Margin | -132.89% | -151.71% | -143.22% | -260.22% | -89.85% |
Free Cash Flow Margin | - | -2.16% | -177.19% | -221.28% | -129.61% |
EBITDA | -315.42 | -335.73 | -547.66 | -591.19 | -247.4 |
EBITDA Margin | -102.81% | -71.30% | -111.46% | -145.45% | -59.49% |
D&A For EBITDA | 29.89 | 29.89 | 40.88 | 80.99 | 34.43 |
EBIT | -345.32 | -365.62 | -588.55 | -672.19 | -281.83 |
EBIT Margin | -112.56% | -77.65% | -119.78% | -165.38% | -67.77% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.